U.S. markets close in 24 minutes

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.40+0.14 (+0.81%)
As of 3:36PM EDT. Market open.
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Currency in USD

Valuation Measures

Yahoo Finance Plus required to access annual data
Yahoo Finance Plus required to access monthly data
Subscribe to Yahoo Finance Plus Essential to download historical data
As of Date: 7/24/2021
Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 7

Trading Information

Stock Price History

Beta (5Y Monthly) 2.62
52-Week Change 3283.56%
S&P500 52-Week Change 336.19%
52 Week High 317.74
52 Week Low 33.30
50-Day Moving Average 316.34
200-Day Moving Average 312.56

Share Statistics

Avg Vol (3 month) 33.54M
Avg Vol (10 day) 32.77M
Shares Outstanding 5177.7M
Implied Shares Outstanding 6N/A
Float 163.4M
% Held by Insiders 10.87%
% Held by Institutions 161.24%
Shares Short (Jun 29, 2021) 419.15M
Short Ratio (Jun 29, 2021) 45.34
Short % of Float (Jun 29, 2021) 412.13%
Short % of Shares Outstanding (Jun 29, 2021) 410.78%
Shares Short (prior month May 27, 2021) 420.01M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2020
Most Recent Quarter (mrq)Mar 30, 2021


Profit Margin 0.00%
Operating Margin (ttm)-592.31%

Management Effectiveness

Return on Assets (ttm)-56.36%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)32.05M
Revenue Per Share (ttm)0.19
Quarterly Revenue Growth (yoy)295.20%
Gross Profit (ttm)-106.83M
EBITDA -189.12M
Net Income Avi to Common (ttm)-209.5M
Diluted EPS (ttm)-1.21
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)240.36M
Total Cash Per Share (mrq)1.35
Total Debt (mrq)289.22M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)2.70
Book Value Per Share (mrq)-0.42

Cash Flow Statement

Operating Cash Flow (ttm)-174.95M
Levered Free Cash Flow (ttm)-112.17M